|
|
 |
|
Viewing report
|
|
|
|
Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application - 2 Volume Set
John Wiley and Sons Ltd, March 2007, Pages: 1,260
Preface 1
Preface 2
A view from Esteve
Dedication and Acknowledgements
List of Contributors
Glossary
VOLUME 1
1 Depressive Disorders
1.1 Introductory and Basic Aspects.
Neurobiology of Mood Disorders (Luz Romero, Ana Montero, Begoña Fernández and José M. Vela).
1.1.1 Definition of mood disorders, impact on a global scale and unmet needs.
1.1.2 Causes and associations in mood disorders: genetics and pharmacogenetics.
1.1.3 Pathogenesis of mood disorders.
1.1.4 Concluding remarks.
References
1.2 Clinics
Clinical Aspects of Depressive Disorders (Rosario Pérez-Egea, Victor Pérez, Dolors Puigdemont and Enric Alvarez).
1.2.1 Introduction.
1.2.2 Classification.
1.2.3 Epidemiology.
1.2.4 Physiopathology.
1.2.5 Treatment of affective disorders.
References
1.3 Pharmacology
Pharmacotherapy of Depression (Begoña Fernández, Luz Romero and Ana Montero).
11.3.1 Introduction.
1.3.2 Current antidepressant treatments.
1.3.3 New strategies for antidepressant treatments.
1.3.4 Concluding remarks.
References
1.4 Experimental Research
Modeling Human Depression by Animal Models (Ana Montero, Begoña Fernández and Luz Romero).
1.4.1 Introduction.
1.4.2 Types of validity.
1.4.3 Animal models of depression.
1.4.4 Some concluding remarks.
References
1.5 Chemistry
Marketed Drugs and Drugs in Development (Jörg Holenz, José Luis Díaz and Helmut Buschmann).
1.5.1 Summary of drug classes.
1.5.2 Tricyclic and tetracyclic antidepressants.
1.5.3 Serotonergic agents.
1.5.4 Noradrenaline reuptake inhibitors.
1.5.5 Monoamine oxidase inhibitors.
1.5.6 Miscellaneous agents.
1.5.7 Compounds launched in single countries.
1.5.8 New opportunities for marketed drugs.
1.5.9 Summary of antidepressants in development.
References
2 Schizophrenia and Other Psychoses
2.1 Introductory and Basic Aspects
Current Status and Challenges in Schizophrenia Research (Francesc Artigas).
2.1.1 Introduction.
2.1.2 Clinical diagnosis and assessment of schizophrenia.
2.1.3 Epidemiology.
2.1.4 Course of schizophrenia.
2.1.5 Brain pathology in schizophrenia.
2.1.6 Pathogenesis and pathophysiology of schizophrenia.
2.1.7 Concluding remarks.
References
2.2 Clinics
Schizophrenia: A Clinical Review (Salvador Ros and Francisco Javier Arranz).
2.2.1 Introduction.
2.2.2 Background.
2.2.3 Epidemiology.
2.2.4 General semiology.
2.2.5 Positive symptoms in schizophrenia.
2.2.6 Negative symptoms in schizophrenia.
2.2.7 Cognitive alterations in schizophrenia.
2.2.8 Characteristics of cognitive deterioration in schizophrenia.
2.2.9 Methods to evaluate cognitive deterioration in schizophrenia.
2.2.10 Affective symptoms in schizophrenia.
2.2.11 Schizophrenia and suicide.
2.2.12 Onset and states.
2.2.13 Etiopathogeny.
2.2.14 Prognosis.
2.2.15 Schizophrenia therapy.
References.
2.3 Pharmacology
Pharmacotherapy of Schizophrenia (Analía Bortolozzi, Llorenç Díaz-Mataix and Francesc Artigas).
2.3.1 Antipsychotic drugs: introduction.
2.3.2 Atypical Antipsychotics: introduction.
2.3.3 Other major investigational approaches.
2.3.4 Concluding remarks: challenges in drug discovery.
References.
2.4 Experimental Research
Modeling schizophrenia in experimental animals (Pau Celada, Anna Castañé, Albert Adell and Francesc Artigas).
2.4.1 Introduction.
2.4.2 Neurophysiology of schizophrenia.
2.4.3 Pharmacological models of schizophrenia.
2.4.4 Neurodevelopmental models.
2.4.5 Genetic models.
2.4.6 Other animal models.
2.4.7 Concluding remarks.
References.
2.5 Chemistry
Marketed Drugs and Drugs in Development (Antonio Párraga, Jörg Holenz and Helmut Buschmann).
2.5.1 Summary of drug classes.
2.5.2 Typical antipsychotics.
2.5.3 Atypical antipsychotics.
2.5.4 Drugs in development.
References.
VOLUME 2
3 Anxiety
3.1 Introductory and Basic Aspects
3.1.1 Definition and classification of anxiety disorders (Francisca López-Ríos, Serafín Gómez-Martín and Antonio Molina-Moreno).
References.
3.1.2 Epidemiology of anxiety disorders (Flor Zaldívar-Basurto and José M. García-Montes).
References.
3.1.3 Etiology of Anxiety (Margarita Moreno, Ginesa López-Crespo and Pilar Flores).
References.
3.1.4 Anxiety disorders and drug abuse (Diana Cardona-Mena, Margarita Moreno and Pilar Flores).
References.
3.1.5 Neurobiology of anxiety (I): Panic disorder, posttraumatic stress disorder, social phobia and obsessive–compulsive disorder (Lola Roldán-Tapia, Ginesa López-Crespo, Francisco Antonio Nieto-Escámez and Diana Cardona-Mena).
References.
3.1.6 Neurobiology of anxiety (II): Childhood anxiety, generalized anxiety disorder and mixed anxiety–depressive disorder (Francisco Antonio Nieto-Escámez, Ginesa López-Crespo, Lola Roldán-Tapia and Fernando Cañadas-Pérez).
References.
3.1.7 Consequences of anxiety on memory processes (I): Introductory and clinical aspects (Fernando Cañadas-Pérez, Francisco Antonio Nieto-Escámez, Lola Roldán-Tapia and Ginesa López-Crespo).
References.
3.1.8 Consequences of anxiety on memory processes (II): Neurobiological aspects (Francisco Nieto-Escámez, Fernando Cañadas-Pérez, Lola Roldán-Tapia and Fernando Sánchez-Santed).
References.
3.2 Clinics
Clinical Aspects of Anxiety (Blanca Gutiérrez and Jorge Cervilla).
3.2.1 Conceptual introduction.
3.2.2 Panic disorder.
3.2.3 Generalized anxiety disorder.
3.2.4 Phobic anxiety disorders.
3.2.5 Obsessive-compulsive disorder.
3.2.6 Conclusion.
References.
3.3 Pharmacology
Pharmacology of Anxiety (José Manuel Baeyens).
3.3.1 Introduction.
3.3.2 Drugs used in treatment of anxiety disorders: an overview.
3.3.3 Generalized anxiety disorder (GAD).
3.3.4 Social anxiety disorder (SAD) or social phobia.
3.3.5 Simple or specific phobia.
3.3.6 Panic disorder (PD).
3.3.7 Posttraumatic stress disorder (PTSD).
3.3.8 Obsessive-compulsive disorder (OCD).
References.
3.4 Experimental Research
Modeling Human Anxiety by Animal Models (Enrique Portillo and José Miguel Vela).
3.4.1 General concepts on animal models.
3.4.2 General aspects of human anxiety.
3.4.3 Animal anxiety.
3.4.4 Potential issues in animal models of anxiety.
3.4.5 Conclusions: Implication for drug discovery.
References.
3.5 Chemistry
Marketed Drugs and Drugs in Development (Mónica García-López, Susana Yenes, Helmut Buschmann and Antoni Torrens).
3.5.1 Summary of drug classes.
3.5.2 Benzodiazepines.
3.5.3 Serotonergic drugs.
3.5.4 GABAergic agents.
3.5.5 Dopaminergic agents.
3.5.6 Serotonin reuptake stimulants.
3.5.7 5-HT2 receptor antagonists.
3.5.8 -adrenoceptor antagonists.
3.5.9 Glucocorticoid receptor antagonists.
3.5.10 GAT-1 inhibitors.
3.5.11 Calcium channel blockers.
3.5.12 No-described mechanism of action.
3.5.13 Drugs in development.
References.
4 Attention Deficit and Hyperactivity Disorders
4.1 Introductory and Basic Aspects
Neurobiological aspects of Attention Deficit and Hyperactivity Disorders (Javier Burgueño, Rafael Franco and Francisco Ciruela).
4.1.1 Definition and introductory clues.
4.1.2 Etiology of ADHD.
References.
4.2 Clinics
Attention Deficit Hyperactivity Disorder: Clinical and Therapeutic Facts (Francisco Javier Arranz and Salvador Ros).
4.2.1 Introduction.
4.2.2 Epidemiology.
4.2.3 Etiology.
4.2.4 Pathophysiology.
4.2.5 Clinical features.
References.
4.3 Pharmacology
Pharmacology: Targets of Drug Action (Francisco Ciruela, Rafael Franco and Javier Burgueño).
4.3.1 Neurobiological evidence for ADHD as an organic phenomenon.
4.3.2 Neurochemistry of ADHD: Neurotransmitter imbalance.
References.
4.4 Chemistry
Marketed Drugs and Drugs in Development (Jörg Holenz, José Luis Díaz and Helmut Buschmann).
4.4.1 Summary of drug classes.
4.4.2 Drugs in development.
References.
Index
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Anxiety Disorders - Viable Indication for Antipsychotics Companies
CNS Drug Discoveries: Schizophrenia Chapter
Anxiety, Phobias & Panic Disorders - 2009 Edition
Are There Changes Ahead for the Generalized Anxiety Disorder Market?
Anxiety Disorders - A Decade of Declining Revenues
Pipeline Insight: Schizophrenia
Strategic Perspectives 2001: Generalized Anxiety Disorder - Driven by Effexor and Open to Expansion
Stakeholder Insight: Anxiety Disorders - More Than Just a Comorbidity
Disease and Therapy Review: Generalized Anxiety Disorder
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
Pipeline and Commercial Insight: Schizophrenia - Second Generation Depots Protect Market Value
Dopamine Transporters : Chemistry, Biology, and Pharmacology
|
|
|
|
